ALIM News and Press, Alimera Sciences Inc. From 10/16/23

ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repor...

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that cli...

2023-10-03 08:17:00 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...

ATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today th...

2023-08-10 14:08:04 ET Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Conference Call August 10, 2023, 09:00 ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Par...

2023-08-10 07:37:20 ET Alimera Sciences press release ( NASDAQ: ALIM ): Q2 GAAP EPS of -$1.32 misses by $1.33 . Revenue of $17.5M (+19.9% Y/Y) misses by $2.95M . The increase was primarily due to the addition of YUTIQ into the U.S. portfolio. Global e...

Alimera Acquired U.S. Commercial Rights to YUTIQ ® Landmark NEW DAY Study Completed Enrollment with over 300 Patients Consolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022 Global End User Demand for ILUVIEN Up 13.5% vs. Se...

Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline ex...

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repor...